Pre-emptive pharmacogenetic (PGx) testing using a multiple gene panel to guide treatment and reduce adverse drug reactions

Topic Status Complete

Pre-emptive pharmacogenetic (PGx) testing using a multiple gene panel to guide treatment decisions

Summary

 

Health Technology Wales researchers searched for evidence on the clinical and cost effectiveness of pre-emptive testing using a PGx panel to guide treatment and reduce adverse drug reactions.

 

The HTW Assessment Group decided not to progress this topic further due to the lack of evidence of effectiveness at present.

Topic Exploration Report

TER465 09.2023

Our advice documents are free to download but we would be grateful if you could help us improve our services by telling us why you are looking at our advice.

Skip form and download file Close

    We may like to contact you by email to find out more about how you used the documents.